| Fiscal Year End | Company Status | Exempt Flag |
| December 31 | Delist | N |
|
|
|
|
|
| Incorporation Locations |
| Inc. Date | Expiry Date | Country | Region | Description |
| 15/Feb/2005 | 14/Feb/2024 | Canada | British Columbia | Business Corporations Act |
|
|
| Exchange Filing Office |
| Location |
| (not available) |
|
|  |
| Business Type(s) |
| Primary/Secondary | Business Type | Details |
| Primary
| *Research And Development In The Life Sciences
| (not available)
|
|
| *Research and Development of Pharmaceutical Products
| News Release June 30, 2014-iCo Therapeutics in-licenses and redefines existing drug candidates or generics by employing reformulation and delivery technologies for new or expanded use indications. The Company has exclusive worldwide rights to two drug candidates - iCo-007 for Diabetic Macular Edema (DME) and iCo-008 for other sight-threatening diseases. iCo-007 is in Phase 2 clinical studies for DME. With Phase 2 clinical history, iCo-008 is targeted for the treatment of keratoconjunctivitis and wet age-related macular degeneration. In addition, iCo holds worldwide rights to an oral drug delivery platform. The first platform candidate is the Oral Amp B Delivery system, utilizing a known anti-fungal drug to treat life-threatening infectious diseases.
|
|
| *Capital Pool Company
| (not available)
|
|
|
| Securities |
| Symbol | Security Name | Market | Status |
| *MSCL | *Satellos Bioscience Inc. | TSX Venture | DELIST |
| *ICO | *iCo Therapeutics Inc | TSX Venture | DELIST |
| *BCL.P | *Beanstalk Capital Ltd. | TSX Venture | DELIST |
|
|
| Name History | From | To |
| *Satellos Bioscience Inc. | 18/Aug/2021 | 14/Feb/2024 |
| *iCo Therapeutics Inc. | 7/Jan/2008 | 17/Aug/2021 |
| *Beanstalk Capital Ltd. | 15/Jun/2006 | 6/Jan/2008 |
|
|
| Company Facts Reconciliation |
| Subject | Date Returned |
| Spring 2015 CFR | Not Received |
|
|
|
|
|
